Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

InMed Pharmaceuticals (INM) Restructuring Costs (2022 - 2024)

InMed Pharmaceuticals' Restructuring Costs history spans 3 years, with the latest figure at $23282.0 for Q2 2024.

  • For Q2 2024, Restructuring Costs rose 128.69% year-over-year to $23282.0; the TTM value through Jun 2024 reached -$37961.0, changed N/A, while the annual FY2024 figure was $80513.0, 42.73% up from the prior year.
  • Restructuring Costs reached $23282.0 in Q2 2024 per INM's latest filing, up from $9768.0 in the prior quarter.
  • In the past five years, Restructuring Costs ranged from a high of $44042.0 in Q4 2022 to a low of -$81147.0 in Q2 2023.
  • Average Restructuring Costs over 3 years is $5753.8, with a median of $16709.0 recorded in 2023.
  • Peak YoY movement for Restructuring Costs: tumbled 76.99% in 2023, then surged 128.69% in 2024.
  • A 3-year view of Restructuring Costs shows it stood at $44042.0 in 2022, then crashed by 76.99% to $10136.0 in 2023, then skyrocketed by 129.7% to $23282.0 in 2024.
  • Per Business Quant, the three most recent readings for INM's Restructuring Costs are $23282.0 (Q2 2024), $9768.0 (Q1 2024), and $10136.0 (Q4 2023).